AllSides Balanced Search reveals information and ideas from all sides of the political spectrum so you can get the full picture.
Feb 20 2024
News
COVID vaccines linked to slight increases in heart, brain, blood disorders
COVID vaccines from companies like Pfizer, Moderna, and AstraZeneca have been linked to rare occurrences of heart, brain, and blood disorders, according to the largest vaccine study to date.
Researchers from the Global Vaccine Data Network analyzed 99 million people who received jabs in eight countries and monitored for increases in 13 medical conditions, Bloomberg News reported.
New York Post (News)Feb 20 2024
News
Largest multicountry COVID study links vaccines to potential adverse effects
A new study on COVID-19 vaccines that looked at nearly 100 million vaccinated individuals affirmed the vaccines’ previously observed links to increased risks for certain adverse effects including myocarditis and Guillain-Barré syndrome.
The study was conducted by the Global COVID Vaccine Safety project and took into account 99,068,901 vaccinated individuals across eight countries:
The HillDec 18 2020
Headline Roundup
FDA Authorizes Moderna's COVID-19 Vaccine
The Food and Drug Administration (FDA) approved biotech company Moderna's COVID-19 coronavirus vaccine for emergency use Friday. Nearly 6 million doses of the vaccine could be distributed as early as this weekend. Moderna developed the drug in partnership with the National Institutes of Health; late-stage clinical trials found it to be nearly 95% effective at preventing the illness.
The
Townhall NBC News (Online) ReutersNov 30 2020
Headline Roundup
Moderna to Ask FDA to Approve Its Vaccine
Biotech company Moderna said it would ask the Food and Drug Administration (FDA) and the European Medicines Agency to allow emergency use of its COVID-19 coronavirus vaccine Monday. New study results suggest the shots offer strong protection, with 94.1% effectiveness.
The FDA approval would likely clear the way for the vaccine to be authorized for use in the United States within weeks
Wall Street Journal (News) Washington Examiner PoliticoOct 29 2020
Headline Roundup
Moderna Advances COVID-19 Vaccine Development
Moderna executives said in a press release Thursday that the company is on track to report early data from a late-stage trial of its experimental COVID-19 coronavirus vaccine, after initial results of its 30,000 person trial come in. The company said it expects to apply for authorization from the Food and Drug Administration (FDA) in early December if all requirements are met. The FDA requires
Newsmax (News) The Hill BloombergJul 27 2020
Headline Roundup
Moderna, NIH Advance Coronavirus Vaccine Trials
In partnership with the National Institutes of Health, biotechnology company Moderna plans to enroll roughly 30,000 subjects in Phase 3 of its COVID-19 coronavirus vaccine trial. The Biomedical Advanced Research and Development Authority have awarded Moderna another $472 million to fill the gap in needed funds. This brings the company's U.S.-based financial backing to roughly $955 million.
The Boston Globe CNET Newsmax (News)Feb 20 2024
News
Largest Covid Vaccine Study Yet Finds Links to Health Conditions
Vaccines that protect against severe illness, death and lingering long Covid symptoms from a coronavirus infection were linked to small increases in neurological, blood, and heart-related conditions in the largest global vaccine safety study to date.
The rare events — identified early in the pandemic — included a higher risk of heart-related inflammation from mRNA shots made by Pfizer
BloombergOct 21 2021
News
CDC gathers to discuss which patient groups should get Moderna and J&J COVID-19 vaccine boosters, and Pfizer reports positive results from booster trial
There was a flurry of positive news on vaccine boosters Thursday, as the Centers for Disease Control and Prevention gathered to discuss which patient groups should be eligible for boosters developed by Moderna and Johnson & Johnson.
The meeting follows a decision Wednesday by the Food and Drug Administration to allow those boosters, marking a big step toward expanding the booster
MarketWatchOct 22 2021
Headline Roundup
CDC Approves Booster Shots from Moderna, J&J
The Centers for Disease Control and Prevention (CDC) on Thursday approved booster shots of the COVID-19 vaccines from Moderna and Johnson & Johnson.
A CDC advisory panel recommended the extra doses Thursday, and CDC director Rochelle Walensky gave her final approval later in the day. The CDC also said people can get a booster of a different vaccine than the one they received
Associated Press CBS News (Online) The Epoch TimesNov 16 2020
News
Moderna's candidate COVID-19 vaccine looks to protect 94.5% of those who get it, trial shows. 'This makes me giddy,' one doctor says.
A second COVID-19 candidate vaccine looks to be even more effective than the first, with both protecting more than 90% of those who get the shots.
Moderna, a Cambridge, Massachusetts-based biotechnology company, announced early Monday that its candidate vaccine, mRNA-1273, developed in collaboration with the U.S. government, appears to be 94.5% effective against the disease.
USA TODAY